文献速递免疫规划传染病防控与疫情报告

口服流感血凝素联合SF-10佐剂诱导局部与全身免疫并提供保护

Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity in mice.
PubMed 文献 · Vaccine · 2018-12-13

该小鼠研究比较了口服流感血凝素疫苗(HAv)联合合成黏膜佐剂SF-10与皮下、鼻内接种的免疫效果。口服HAv-SF-10诱导的血清IgA/IgG及多种黏膜部位分泌型IgA/IgG水平显著高于皮下或鼻内接种,并产生高于霍乱毒素佐剂的保护性免疫。

要点

  • 口服HAv-SF-10诱导的黏膜和全身抗体应答显著优于皮下或鼻内接种。
  • 口服HAv-SF-10对重症流感A病毒感染的保护性免疫显著高于HAv联合霍乱毒素。
  • SF-10促进抗原被肠道MHC II+CD11c+树突状细胞及其CD11b+CD103+/-亚群摄取。

核心结论

  • 口服HAv-SF-10可诱导比鼻内或皮下接种更有效的全身和局部免疫,并在多种黏膜器官产生高水平的分泌型HAv特异性IgA和保护性免疫。

研究设计与样本

  • 小鼠实验研究,比较口服HAv-SF-10与皮下注射HAv或鼻内接种HAv及HAv-SF-10的免疫效果。
  • 以卵清蛋白为模型抗原评估SF-10对肠道抗原提呈细胞摄取的影响。

主要发现

  • 口服HAv-SF-10诱导血清HAv特异性IgA和IgG,以及支气管肺泡灌洗液、鼻洗液、胃提取物和粪便中的分泌型IgA和IgG,水平显著高于皮下HAv或鼻内HAv及HAv-SF-10接种。
  • 口服HAv-SF-10后胃肠道和呼吸道黏膜淋巴组织中HAv特异性IgA和IgG抗体分泌细胞数量高,而单独口服HAv无或极低诱导。
  • 口服HAv-SF-10对重症流感A病毒感染的保护性免疫显著高于HAv联合霍乱毒素。
  • 口服HAv-SF-10后脾细胞经HAv刺激产生独特细胞因子模式:Th17细胞因子(如IL-17A和IL-22)显著诱导,Th1细胞因子(如IL-2和IFN-γ)高诱导,Th2细胞因子(如IL-4和IL-5)中等诱导。

临床怎么用

  • 提示口服HAv-SF-10可能作为诱导黏膜和全身免疫的流感疫苗候选策略,但尚未在人体验证。

局限性

  • 研究仅在小鼠中进行,对人体安全性和免疫原性尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We reported previously that a synthetic mucosal adjuvant SF-10, which mimics human pulmonary surfactant, delivers antigen to mucosal dendritic cells in the nasal cavity and promotes induction of humoral and cellular immunity. The aim of the present study was to determine the effects of oral administration of antigen combined with SF-10 (antigen-SF-10) on systemic and local immunity. Oral administration of ovalbumin, a model antigen, combined with SF-10 enhanced ovalbumin uptake into intestinal antigen presenting MHC II+CD11c+ cells and their CD11b+CD103+ and CD11b+CD103- subtype dendritic cells, which are the major antigen presenting subsets of the intestinal tract, more efficiently compared to without SF-10. Oral vaccination with influenza hemagglutinin vaccine (HAv)-SF-10 induced HAv-specific IgA and IgG in the serum, and HAv-specific secretory IgA and IgG in bronchoalveolar lavage fluid, nasal washes, gastric extracts and fecal material; their levels were significantly higher than those induced by subcutaneous HAv or intranasal HAv and HAv-SF-10 vaccinations. Enzyme-linked immunospot assay showed high numbers of HAv-specific IgA and IgG antibody secreting cells in the gastrointestinal and respiratory mucosal lymphoid tissues after oral vaccination with HAv-SF-10, but no or very low induction following oral vaccination with HAv alone. Oral vaccination with HAv-SF-10 provided protective immunity against severe influenza A virus infection, which was significantly higher than that induced by HAv combined with cholera toxin. Oral vaccination with HAv-SF-10 was associated with unique cytokine production patterns in the spleen after HAv stimulation; including marked induction of HAv-responsive Th17 cytokines (e.g., IL-17A and IL-22), high induction of Th1 cytokines (e.g., IL-2 and IFN-γ) and moderate induction of Th2 cytokines (e.g., IL-4 and IL-5). These results indicate that oral vaccination with HAv-SF-10 induces more efficient systemic and local immunity than nasal or subcutaneous vaccination with characteristically high levels of secretory HAv-specific IgA in various mucosal organs and protective immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kimoto T, Kim H, Sakai S, et al. Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity in mice. Vaccine. 2018. PMID: 30553569. doi:10.1016/j.vaccine.2018.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。